Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keyur Shah

Advanced Heart Failure and Transplant Cardiology Richmond,, VA Medical Doctor

NPI 1396886362 CMS profile 63146

1250 E Marshall Street, Richmond,, VA 23298

Open in the dashboard

General payments

$62,089

182 records reported · program years 2019–2025

Research payments

$61,170

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$511,265 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Keyur Shah of Richmond,, VA is reported in the CMS Open Payments database as having received $62,089 across 182 general payments and $61,170 in research payments paid to them. Separately, studies naming them as principal investigator received $511,265 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,568 39
2024 General $3,463 29
2023 General $2,694 23
2022 General $1,920 13
2021 General $5,435 18
2021 Research $940 1
2020 General $12,474 14
2020 Research $4,180 2
2019 General $17,536 46
2019 Research $56,050 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keyur Shah
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Keyur Shah were reported at $18,568. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Keyur Shah Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $17,536 $863 $224–$4,562 $163
2020 $12,474 $452 $122–$3,992 $114
2021 $5,435 $550 $159–$3,571 $132
2022 $1,920 $729 $221–$4,357 $149
2023 $2,694 $1,002 $309–$5,827 $160
2024 $3,463 $931 $273–$5,204 $164
2025 $18,568 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Akcea Therapeutics, Inc. $14,563 18 payments
  2. AstraZeneca Pharmaceuticals LP $12,706 14 payments
  3. Pfizer Inc. $9,989 12 payments
  4. Alnylam Pharmaceuticals Inc. $5,596 12 payments
  5. Medtronic Vascular, Inc. $5,190 19 payments
  6. Abbott Laboratories $4,215 50 payments
  7. BridgeBio Pharma, Inc. $3,910 1 payment
  8. Alexion Pharmaceuticals, Inc. $1,941 13 payments
  9. Abiomed $1,489 8 payments
  10. CVRx, Inc. $767 7 payments
  11. Other $1,724 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $19,473 5 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,042 11 payments
  3. Honoraria $11,525 6 payments
  4. Food and Beverage $10,479 144 payments
  5. Travel and Lodging $3,289 11 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $249 1 payment
  7. Education $32 4 payments
Products named General payments · program years 2019–2025
  1. TEGSEDI $14,563 18 payments
  2. WAINUA $12,322 8 payments
  3. ONPATTRO $5,281 8 payments
  4. HeartWare HVAD $5,190 19 payments
  5. Attruby $3,910 1 payment
  6. Impella $1,252 5 payments
  7. CARDIOMEMS $1,032 10 payments
  8. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $854 10 payments
  9. Barostim Neo System $767 7 payments
  10. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $538 7 payments
  11. Other $3,670 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Ortho-Clinical Diagnostics, Inc. $59,900 2 payments
  2. Pfizer Inc. $1,270 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,057

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$6,819,446

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

41.2%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 204 $4,956,358
Vyndaqel Tafamidis Meglumine Brand 59 $1,183,153
Entresto Sacubitril/Valsartan Brand 179 $207,207
Farxiga Dapagliflozin Propanediol Brand 156 $179,335
Jardiance Empagliflozin Brand 108 $107,800
Eliquis Apixaban Brand 98 $91,268
Sandostatin Lar Depot Octreotide Acetate,mi-Spheres Brand 12 $59,252
Xarelto Rivaroxaban Brand 15 $12,781
Torsemide Generic 108 $3,327
Eplerenone Generic 44 $3,324

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$57,202

Medicare's payments for the services billed

Medicare patients

263

Average age 71

Services billed

1,087

95 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Chronic kidney disease 63%
Atrial fibrillation 57%
Ischemic heart disease 56%
Diabetes 51%
Arthritis 49%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $126
$126 59 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $101
$101 — —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

186 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record